Sugar is Not Your Friend

Introduction and Objective: The efficacy and safety of the daily oral, non-peptide GLP-1RA orforglipron (OFG) were assessed as add-on to insulin glargine with/without metformin and/or SGLT-2 inhibitors in adults with type 2 diabetes (T2D) (ACHIEVE-5; NCT06109311).Methods: In this 40-week double-blind, randomized, placebo-controlled, phase 3 study, participants with T2D and inadequate glycemic control were randomized (1:1:1:1) […]

Introduction and Objective: Central KATP channel activation with diazoxide (DZX) suppresses endogenous glucose production (EGP) in rodents and humans (JCI 121:4916, 2011), suggesting that brain signals help regulate glucose metabolism. This regulation may require adequate insulin levels (Diabetes 60:3132, 2011). Since previous studies were performed at insulin levels ~20 µU/ml, we evaluated this regulation under […]

Introduction and Objective: We previously showed that SGLT2 inhibitors stimulate endogenous glucose production, offsetting their glucosuria-induced glucose lowering action, and that this effect is not explained by changes in plasma glucose, insulin, or glucagon concentration using a pancreatic clamp. To investigate the impact of Empagliflozin (an SGLT2 inhibitor) on fasting hepatic glucose production (HGP), gluconeogenic […]